Evidence map›Paper›PMID 38594241›Full record

ArticleBlood cancer journal2024

A novel small molecule inhibitor of CD73 triggers immune-mediated multiple myeloma cell death.

Arghya Ray, Ting Du, Xueping Wan, Yan Song, Sindhu C Pillai, Md Abu Musa, Teng Fang, Jared Moore, Brian Blank, Xiaohui Du and 10 more

Open access · goldAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Amoeboid cancer cells at a glance.Journal of cell science · 2026
    Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 2 institutions in 1 country.

Arghya RayThe LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. arghya_ray@dfci.harvard.edu.ORCID 0000-0002-0652-2905
Ting DuThe LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Xueping WanThe LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Yan SongThe LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-6729-2672
Sindhu C PillaiThe LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Md Abu MusaThe LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-0662-0078
Teng FangThe LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Jared MooreORIC Pharmaceuticals, Inc., South San Francisco, CA, USA.
Brian BlankORIC Pharmaceuticals, Inc., South San Francisco, CA, USA.
Xiaohui DuORIC Pharmaceuticals, Inc., South San Francisco, CA, USA.
Xi ChenORIC Pharmaceuticals, Inc., South San Francisco, CA, USA.
Robert WarneORIC Pharmaceuticals, Inc., South San Francisco, CA, USA.
Dena SutimantanapiORIC Pharmaceuticals, Inc., South San Francisco, CA, USA.
Fang LuiORIC Pharmaceuticals, Inc., South San Francisco, CA, USA.
Tatiana ZavorotinskayaORIC Pharmaceuticals, Inc., South San Francisco, CA, USA.
Christophe ColasORIC Pharmaceuticals, Inc., South San Francisco, CA, USA.
Lori FriedmanORIC Pharmaceuticals, Inc., South San Francisco, CA, USA.
Melissa R JunttilaORIC Pharmaceuticals, Inc., South San Francisco, CA, USA.
Dharminder Chauhan *The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Dharminder_Chauhan@dfci.harvard.edu.ORCID 0000-0002-5548-6138
Kenneth C Anderson *The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Kenneth_Anderson@dfci.harvard.edu.ORCID 0000-0002-6418-0886
Sunesis (United States) · USDana-Farber Cancer Institute · US

Funding

Targeting Genomic Instability and Evolution in MyelomaP01CA155258 · NCI · DANA-FARBER CANCER INST · PI Jill Corre · 2011 to 2026
$32.5M
Role of Cytokines in Myeloma PathogenesisR01CA050947 · NCI · DANA-FARBER CANCER INSTITUTE · PI ANDERSON, KENNETH C., MITSIADES, CONSTANTINE S. · 1991 to 2018
$5.1M
Therapeutically Targeting Plasmacytoid Dendritic Cells in Multiple MyelomaR01CA207237 · NCI · DANA-FARBER CANCER INST · PI ANDERSON, KENNETH C., CHAUHAN, DHARMINDER · 2016 to 2020
$2.0M
NCI NIH HHS P01 CA155258NCI NIH HHS R01 CA050947NCI NIH HHS R01 CA207237
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Multiple MyelomaCell DeathCell Line, TumorHumans

Identifiers

PMID38594241
PMCPMC11004003
OpenAlexW4394615084

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.